Catalent (NYSE:CTLT) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Friday.
A number of other brokerages have also weighed in on CTLT. Needham & Company LLC restated a “hold” rating on shares of Catalent in a report on Monday, October 23rd. Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research report on Friday, November 3rd. BidaskClub raised shares of Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, October 5th. Piper Jaffray Companies lifted their target price on shares of Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 7th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and issued a $39.00 target price (up previously from $30.00) on shares of Catalent in a research report on Thursday, August 31st. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $44.25.
Shares of Catalent (NYSE:CTLT) traded down $0.99 on Friday, reaching $38.80. 612,803 shares of the company’s stock traded hands, compared to its average volume of 894,161. Catalent has a twelve month low of $23.03 and a twelve month high of $43.39. The stock has a market capitalization of $5,154.93, a price-to-earnings ratio of 27.13, a PEG ratio of 2.49 and a beta of 1.42. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01.
In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was purchased at an average price of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.70% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in shares of Catalent by 15.2% during the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock valued at $614,695,000 after buying an additional 2,316,849 shares in the last quarter. Vanguard Group Inc. grew its holdings in Catalent by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock valued at $355,192,000 after purchasing an additional 369,526 shares during the last quarter. Janus Henderson Group PLC bought a new position in Catalent during the 2nd quarter valued at about $239,629,000. JPMorgan Chase & Co. grew its holdings in Catalent by 4.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,139,690 shares of the company’s stock valued at $180,403,000 after purchasing an additional 226,705 shares during the last quarter. Finally, State Street Corp grew its holdings in Catalent by 10.7% during the 2nd quarter. State Street Corp now owns 4,315,841 shares of the company’s stock valued at $151,488,000 after purchasing an additional 418,196 shares during the last quarter. Institutional investors own 99.44% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Catalent (CTLT) Downgraded to Hold at ValuEngine” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/03/catalent-ctlt-downgraded-to-hold-at-valuengine.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.